Last reviewed · How we verify
E39 vaccine then J65 vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
E39 vaccine then J65 vaccine (E39 vaccine then J65 vaccine) — COL George Peoples, MD, FACS.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| E39 vaccine then J65 vaccine TARGET | E39 vaccine then J65 vaccine | COL George Peoples, MD, FACS | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- E39 vaccine then J65 vaccine CI watch — RSS
- E39 vaccine then J65 vaccine CI watch — Atom
- E39 vaccine then J65 vaccine CI watch — JSON
- E39 vaccine then J65 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). E39 vaccine then J65 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/e39-vaccine-then-j65-vaccine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab